Profile data is unavailable for this security.
About the company
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
- Revenue in USD (TTM)0.00
- Net income in USD-146.66m
- Incorporated2023
- Employees91.00
- LocationApogee Therapeutics Inc221 Crescent St.Building 17, Suite 102bWALTHAM 02453United StatesUSA
- Phone+1 (650) 394-5230
- Fax+1 (302) 655-5049
- Websitehttps://apogeetherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azenta Inc | 656.32m | -164.17m | 2.23bn | 3.30k | -- | 1.17 | -- | 3.39 | -2.97 | -2.97 | 12.31 | 38.82 | 0.2633 | 3.23 | 3.71 | -- | -6.59 | -2.07 | -7.18 | -2.31 | 40.13 | 43.11 | -25.01 | -8.76 | 3.50 | -- | -- | -- | -1.32 | -3.41 | -1,174.32 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.27bn | 525.00 | -- | 6.87 | -- | 115.66 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Ideaya Biosciences Inc | 3.92m | -178.12m | 2.30bn | 124.00 | -- | 1.95 | -- | 586.20 | -2.32 | -2.32 | 0.0515 | 13.67 | 0.0044 | -- | 1.17 | 31,629.03 | -20.09 | -19.17 | -20.87 | -21.05 | -- | -- | -4,541.56 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.48 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -131.16m | 2.36bn | 33.00 | -- | 8.47 | -- | -- | -3.31 | -3.31 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -72.82 | -53.90 | -82.94 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Geron Corp | 29.48m | -201.19m | 2.43bn | 141.00 | -- | 8.29 | -- | 82.43 | -0.3221 | -0.3221 | 0.0469 | 0.4846 | 0.0687 | -- | 1.31 | 209,078.00 | -46.90 | -51.32 | -63.81 | -64.90 | 97.29 | -- | -682.47 | -19,949.13 | 2.74 | -- | 0.2229 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Janux Therapeutics Inc | 13.05m | -60.54m | 2.44bn | 64.00 | -- | 3.71 | -- | 187.02 | -1.18 | -1.18 | 0.2548 | 12.54 | 0.0241 | -- | -- | 203,890.60 | -11.19 | -- | -11.53 | -- | -- | -- | -463.91 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Protagonist Therapeutics Inc | 323.80m | 170.85m | 2.45bn | 126.00 | 15.57 | 4.66 | 14.28 | 7.58 | 2.68 | 2.68 | 5.24 | 8.94 | 0.6935 | -- | 236.87 | 2,891,027.00 | 36.59 | -35.90 | 39.67 | -41.36 | -- | -- | 52.76 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Scholar Rock Holding Corp | 0.00 | -225.97m | 2.50bn | 150.00 | -- | 26.97 | -- | -- | -2.36 | -2.36 | 0.00 | 0.9889 | 0.00 | -- | -- | 0.00 | -105.14 | -38.14 | -124.25 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.3875 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Apogee Therapeutics Inc | 0.00 | -146.66m | 2.51bn | 91.00 | -- | 3.32 | -- | -- | -2.67 | -2.67 | 0.00 | 12.91 | 0.00 | -- | -- | 0.00 | -24.39 | -- | -25.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 2.51bn | 557.00 | -- | 3.25 | -- | 27.64 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Belite Bio Inc (ADR) | 0.00 | -33.03m | 2.52bn | 20.00 | -- | 22.69 | -- | -- | -1.11 | -1.11 | 0.00 | 3.63 | 0.00 | -- | -- | 0.00 | -38.10 | -- | -38.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 929.24m | 128.51m | 2.69bn | 620.00 | 20.87 | 4.66 | 19.12 | 2.90 | 0.7753 | 0.7753 | 5.60 | 3.47 | 1.15 | 1.91 | 9.73 | 1,556,509.00 | 15.97 | -27.50 | 24.34 | -32.73 | 91.61 | 95.62 | 13.83 | -38.35 | 2.11 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| SpringWorks Therapeutics Inc | 135.49m | -275.16m | 2.70bn | 305.00 | -- | 5.08 | -- | 19.90 | -3.89 | -3.89 | 1.89 | 7.15 | 0.2517 | -- | -- | 444,219.70 | -51.12 | -36.97 | -57.59 | -39.49 | 94.52 | -- | -203.09 | -2,176.46 | 6.02 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 2.82bn | 184.00 | -- | 3.16 | -- | 32.18 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Data as of Nov 22 2024. Currency figures normalised to Apogee Therapeutics Inc's reporting currency: US Dollar USD
65.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 7.02m | 15.61% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 4.70m | 10.44% |
| RTW Investments LPas of 30 Sep 2024 | 2.71m | 6.03% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.71m | 6.02% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 2.53m | 5.63% |
| Fairmount Funds Management LLCas of 30 Sep 2024 | 2.05m | 4.55% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.04m | 4.52% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 2.02m | 4.48% |
| RA Capital Management LPas of 30 Sep 2024 | 1.96m | 4.36% |
| Braidwell LPas of 30 Sep 2024 | 1.64m | 3.65% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
